ストックスクリーナーアプリを入手
139.37
2.22%
3.03
アフターアワーズ：
139.96
0.59
+0.42%
前日終値:
$136.34
開ける：
$137.18
24時間の取引高:
7.72M
Relative Volume:
1.12
時価総額：
$172.99B
収益：
$29.45B
当期純損益:
$8.51B
株価収益率:
20.55
EPS:
6.7823
ネットキャッシュフロー:
$9.46B
1週間 パフォーマンス:
+0.91%
1か月 パフォーマンス:
-6.43%
6か月 パフォーマンス:
+25.56%
1年 パフォーマンス:
+24.38%
1日の値動き範囲:
$137.17
$140.35
1週間の範囲:
$133.89
$141.70
52週間の値動き範囲:
$93.37
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Compare GILD vs LLY, JNJ, ABBV, AZN, MRK
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
139.37 | 169.23B | 29.45B | 8.51B | 9.46B | 6.7823 |
LLY
Lilly Eli Co
|
919.77 | 792.08B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
244.44 | 584.06B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
217.49 | 376.96B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
197.22 | 300.68B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.29 | 291.99B | 64.93B | 18.26B | 12.36B | 7.2751 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | 開始されました | Jefferies | Buy |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-11 | 繰り返されました | Needham | Buy |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing - Yahoo Finance
Gilead Sciences Inc. stock rises Tuesday, still underperforms market - MarketWatch
Bernstein Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $160 - Moomoo
UBS reiterates Gilead Sciences stock rating on strong Yeztugo sales - Investing.com
Gilead Sciences Inc Stock (GILD) Moved Up by 3.62% on Mar 31: A Full Analysis - TradingKey
Gilead and its new HIV prevention drug are in the sights of a well-known humanitarian group - The Business Journals
MSF denied access to Gilead HIV-prevention drug - EU Reporter
2 Defensive Dividend Payers Growing Fast on AI Demand - Investing.com
Gilead (GILD) Enters Agreement to Acquire Ouro Medicines - GuruFocus
J. Safra Sarasin Holding AG Has $100.57 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Boston Common Asset Management LLC Sells 15,833 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Expands Autoimmune Ambitions With Ouro Deal And Galapagos Collaboration - Yahoo Finance
Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases - The Manila Times
Insider Sell: Daniel O'Day Sells 10,000 Shares of Gilead Sciences Inc (GILD) - GuruFocus
[Press release] Médecins Sans Frontières: Gilead refuses to sell groundbreaking HIV prevention drug to MSF - European AIDS Treatment Group
Gilead Sciences (NASDAQ: GILD) CEO sells 10,000 shares under 10b5-1 plan - Stock Titan
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Doctors Without Borders calls Gilead 'unconscionable' for refusing to sell HIV prevention drug to organization - statnews.com
Gilead refuses to sell groundbreaking HIV prevention drug to MSF - MSF Access
Open letter to Gilead: Prevention should not be a privilege - Doctors Without Borders
Gilead to acquire Ouro Medicines in $2.18B deal, expand inflammation pipeline - MSN
Nomura VIP Core Equity Series's Gilead Sciences Inc(GILD) Holding History - GuruFocus
Beacon Investment Advisory Services Inc. Buys 10,449 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Stake Lifted by USA Financial Formulas - MarketBeat
Wedge Capital Management L L P NC Reduces Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Synergy Asset Management LLC Has $204,000 Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Exchange Traded Concepts LLC Raises Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences: Caution After A Re-Rating Amidst New Concentration Risks (NASDAQ:GILD) - Seeking Alpha
Why Gilead Sciences (GILD) Dipped More Than Broader Market Today - Yahoo Finance
Gilead: Why The 'Immune System Company' Pivot Is No Longer A Bargain (Downgrade) (GILD) - Seeking Alpha
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch
Daniel O'Day sells shares at Gilead Sciences (NASDAQ: GILD) - Stock Titan
Gilead Sciences Inc Stock: Strong HIV Franchise and Dividend Growth Position Shares for Long-Term Va - AD HOC NEWS
Deutsche Bank reiterates Buy on Gilead Sciences stock, $155 target - Investing.com
Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic? - Yahoo Finance
Can Gilead's Recent Acquisitions Strengthen Its Long-Term Growth Outlook? - tradingview.com
Fierce Pharma Asia—Takeda’s $1.3B reorg; India’s GLP-1 floodgates; Gilead’s $2.2B buy of a China NewCo - Fierce Pharma
Gilead Sciences FY2026 EPS Increased by Erste Group Bank - MarketBeat
Gilead Sciences, Inc. $GILD Shares Purchased by Global X Japan Co. Ltd. - MarketBeat
Rx Rundown: Merck, Gilead Sciences and Sanofi and more - Medical Marketing and Media
NatWest Group plc Has $5.40 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences nears $2B deal for Ouro MedicinesFT - MSN
GILD Stock Price, Quote & Chart | GILEAD SCIENCES INC (NASDAQ:GILD) - ChartMill
A Look At Gilead Sciences (GILD) Valuation After Recent Share Price Weakness - simplywall.st
Gilead to Acquire Ouro Medicines in $2.18B Deal, Expand Inflammation Pipeline - Insider Monkey
Gilead Sciences stock consolidates as executive spotlights new HIV prevention development approach - Traders Union
Vanguard disaggregates holdings; GILD reporting shows 0 shares (Vanguard) - stocktitan.net
Gilead Sciences Inc (XSWX:GILD) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
The Unprecedented Role Manufacturing Innovation Played in Shaping Gilead’s Long-Acting HIV Prevention Therapy - Gilead Sciences
Czech National Bank Buys 12,009 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Assenagon Asset Management S.A. Has $32.78 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
4.14%
大文字化:
|
ボリューム (24 時間):